Presentation (CTI)

OBJECTIVES: Navigating market access across the global reimbursement landscape is a multifaceted challenge, influenced by each individual country’s clinical unmet need, healthcare budget, regulatory requirements, and market conditions. In this research, we analysed trends across global HTA markets to gain insights into reimbursement trends and investigate discrepancies in access.
METHODS: All reimbursement decisions published in 2024 across 14 global HTA markets were reviewed, with data extracted on the number of distinct products assessed, the number of indications targeted across all submissions, and the outcome of all included reimbursement decisions. Further analysis to investigate the discrepancies in reimbursement outcomes across markets was conducted, using matched HTA submissions (where a product was assessed by several HTA bodies for the same indication) to determine the level of divergence.
RESULTS: In 2024, a total of 2,293 reimbursement decisions were made based on HTA submissions, covering 573 distinct products across 440 indications. Whilst the average rate of achieving successful reimbursement was 79%, this varied greatly between countries ranging from 20% (Norway) to 100% (Germany). Furthermore, for matched submissions across different markets, the likelihood of achieving the same outcome was only 61%. This divergence in outcomes may impact the number of products made available in each market, and consequently access to medicines for patients - demonstrated by only 11 new products made available for Norway versus 89 in Germany.
CONCLUSIONS: Global variation in the availability of new products reflects differing HTA body perspectives and priorities across markets, contributing to inequities in patient access. While such variabilities will continue to present in the ever-evolving market access landscape, these findings underscore the need for improved alignment and standardised assessment approaches to support equitable access - particularly relevant for the EU, where the implementation of Joint Clinical Assessments may help address this.